Skip to main content

2 No-Brainer Dividend Stocks to Buy With $250 in 2025


Dividend investing remains one of the most reliable strategies for growing wealth and generating passive income. Whether you’re a seasoned investor or just starting, dividend stocks can provide a steady stream of returns while offering the potential for capital appreciation. The choice often boils down to two paths: seeking businesses with rapid dividend growth (but often lower yields) or focusing on high-yield stocks (though these may carry greater risk).

If you’re looking for a blend of these two approaches, AbbVie (NYSE: ABBV) and W.P. Carey (NYSE: WPC) are standout choices for 2025. With just $250, you can invest in these resilient, income-generating companies and set the foundation for long-term financial gains.

1. AbbVie: A Biopharma Giant Built for Dividend Growth

AbbVie has been a dividend investor's dream since its 2013 spinoff from Abbott Laboratories. Over the past decade, the company has raised its dividend by an impressive 310%, demonstrating its commitment to rewarding shareholders. Despite its consistent growth, AbbVie still offers an attractive dividend yield of around 3.6% at recent prices, making it a standout option for investors seeking a balance of income and growth.

Why AbbVie Is a No-Brainer Dividend Stock

AbbVie’s ability to consistently grow its dividend stems from a robust portfolio of high-performing drugs and innovative research and development. Here’s what makes this company a must-have for dividend investors in 2025:

A Resilient Drug Portfolio

AbbVie’s flagship drug, Skyrizi, has become a market leader in treating psoriasis since its 2019 launch. The drug generated $7.9 billion in revenue during the first nine months of 2024, reflecting a 48% year-over-year growth. Another standout is Rinvoq, an arthritis treatment launched the same year, with sales climbing 52% to $4.1 billion over the same period.

These blockbuster drugs more than compensate for revenue declines from AbbVie’s older products, such as Humira, which faces competition from biosimilars.

A Promising Pipeline

In 2023, AbbVie invested $8.7 billion in Cerevel Therapeutics, a bold move that seemed questionable after initial setbacks with the schizophrenia drug Emraclidine. However, Cerevel’s Tavapadon, a novel treatment for Parkinson’s disease, delivered positive results in its phase 3 trials. If approved, Tavapadon could generate billions in annual revenue, further strengthening AbbVie’s cash flow.

Sustainable Dividend Growth

AbbVie’s free cash flow over the past 12 months reached $15.6 billion, and the company used just 70% of this to cover its dividend obligations. This conservative payout ratio, combined with the growth potential of Skyrizi, Rinvoq, and Tavapadon, suggests AbbVie can sustain and even accelerate dividend increases in the years ahead.

Why Now Is the Time to Buy AbbVie

Despite its strong fundamentals, AbbVie’s stock has faced recent pressure due to concerns over its Cerevel investment and broader market trends. These temporary challenges present a prime opportunity for long-term investors to acquire shares at an attractive price. AbbVie’s track record of innovation, robust drug pipeline, and commitment to shareholder returns make it a no-brainer buy for 2025.

2. W.P. Carey: A High-Yield REIT with Stability

Real estate investment trusts (REITs) are a popular choice for dividend investors because they are legally required to distribute at least 90% of their taxable income to shareholders. W.P. Carey, one of the most diversified REITs in the market, is a standout performer with a 6.4% dividend yield, offering investors a compelling opportunity for high income and long-term growth.

What Sets W.P. Carey Apart

W.P. Carey specializes in net-lease agreements, where tenants are responsible for property taxes, insurance, and maintenance. This business model provides steady cash flow and reduces the REIT’s exposure to fluctuating operating expenses. Here’s why W.P. Carey is an excellent pick for 2025:

A Diversified Portfolio

W.P. Carey’s portfolio spans industrial, retail, warehouse, and self-storage properties. Its largest tenant, Extra Space Storage, contributes just 2.7% of the REIT’s annualized base rent, highlighting the company’s diversification and resilience to economic downturns.

Navigating Challenges

In 2023, W.P. Carey made the strategic decision to spin off its office properties into a separate entity. While this move resulted in a temporary dividend cut, it strengthened the REIT’s overall portfolio by reducing its exposure to declining office rents. Since then, W.P. Carey has raised its dividend four times, signaling its commitment to shareholders.

Strong Financials and Dividend Sustainability

Despite the challenges of rising interest rates, W.P. Carey remains on solid financial footing. The REIT’s adjusted funds from operations (AFFO), a key metric for evaluating REITs, is expected to reach $4.68 per share in 2025. With an annual dividend payout of just $3.52 per share, there’s plenty of room for further increases.

Why Now Is the Time to Buy W.P. Carey

W.P. Carey’s stock price has been under pressure due to macroeconomic factors, such as rising Treasury yields, which often lead to a sell-off in income-generating assets like REITs. However, these short-term fluctuations create a compelling entry point for long-term investors.

With a high dividend yield, a diversified portfolio, and a track record of managing challenges effectively, W.P. Carey is well-positioned to deliver stable returns in 2025 and beyond.

How to Invest $250 in These Dividend Stocks

Even with a modest investment of $250, you can start building a portfolio that generates passive income and offers growth potential. Here’s how you might allocate your investment:

  1. AbbVie (50% Allocation): Use $125 to purchase AbbVie shares. This provides exposure to a rapidly growing biopharma company with a strong dividend history and a promising pipeline.

  2. W.P. Carey (50% Allocation): Invest the remaining $125 in W.P. Carey. This allocation ensures a high dividend yield and diversification through a stable, income-generating REIT.

Final Thoughts

Investing in dividend stocks like AbbVie and W.P. Carey offers a powerful combination of income and growth. These companies are leaders in their respective industries, with strong fundamentals and a commitment to rewarding shareholders. By investing $250 in these no-brainer stocks, you can take advantage of current market opportunities and lay the groundwork for long-term financial success.

As always, ensure your investments align with your financial goals and risk tolerance. Whether you’re seeking passive income, portfolio diversification, or both, AbbVie and W.P. Carey are compelling choices to consider in 2025.

Labels:

Comments

Post a Comment

Popular posts from this blog

Nebius: A 10x AI Growth Story Still Flying Under Wall Street’s Radar

In the world of explosive AI growth stories, few companies combine the stealth, ambition, and scale of Nebius Group N.V. (NASDAQ: NBIS). While Wall Street fawns over the Magnificent Seven and scrambles to understand how OpenAI, Anthropic, and others fit into the commercial AI puzzle, Nebius is quietly building a European AI infrastructure empire—and it’s about to cross the Atlantic. Despite a 20% decline in the stock since February 2025, the company is arguably one of the most compelling under-the-radar growth stories in AI today. If you're a long-term investor searching for the next 10-bagger hiding in plain sight, this one deserves your attention. The Dip Isn't the Story—The Growth Is Let’s begin with the obvious: Nebius stock is down 20% from its recent high. For most momentum chasers, that's a red flag. But the market correction has been broad-based, with the S&P 500 itself in the throes of a selloff sparked by political uncertainty and concerns over rates. Th...
Post a Comment
Read more

Supercharge Your Retirement With Income Machines Paying Fat Dividends

Retirement planning can be a daunting task, but building a portfolio filled with reliable, high-yielding dividend stocks and funds can make it significantly easier. Instead of relying on the traditional 4% rule, where you gradually sell assets to fund your retirement, you can live off dividends indefinitely, preserving your principal while enjoying a steady income stream. By focusing on investments with strong, durable business models, robust balance sheets, and dividend growth that outpaces inflation, retirees can achieve financial security and even benefit from market downturns by reinvesting excess cash flow. In this article, we’ll explore six income-generating investments—three funds and three individual stocks—that can help supercharge your retirement. Fund #1: Schwab U.S. Dividend Equity ETF (SCHD) SCHD is a go-to dividend growth ETF with a well-balanced portfolio of 101 high-quality companies. While its 3.6% dividend yield may be on the lower end for some retirees, its consisten...
Post a Comment
Read more

Higher High, Lower High; AMD Is A Buy

In the ever-volatile world of semiconductors, Advanced Micro Devices (NASDAQ: AMD) (TSX: AMD:CA) is showing all the hallmarks of a classic breakout opportunity—one that savvy investors would be wise not to overlook. Despite a near 50% pullback from its peak, AMD's fundamentals have never looked stronger. And while investor sentiment has temporarily soured, the underlying growth momentum tells a completely different story. We’re witnessing the convergence of a rare market anomaly: robust fundamentals + depressed valuation = opportunity. This is a textbook “higher high, lower high” setup in technical and sentiment terms—when a strong company’s fundamentals climb higher even as its stock price dips lower. Eventually, these two trends reconcile, and when they do, patient investors often see outsized gains. Table of Contents AMD: From Hero to Underdog—Again Unpacking AMD’s Growth Narrative Why the Momentum Is Not Just Sustainable—But Accelerating The Market Is Pricing AMD ...
Post a Comment
Read more